Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Benefits and Charges (Details) - USD ($) $ in Millions		12 Months Ended
		Dec. 31, 2019		Dec. 31, 2018		Dec. 31, 2017
Restructuring Reserve [Roll Forward]
Beginning balance		$ 45	[1]	$ 41		$ 90
Provision/(benefit)		33		26		13
Utilization and other	[2]	(33)		(22)		(62)
Ending balance		45	[1]	45	[1]	41
Other current liabilities
Restructuring Reserve [Roll Forward]
Accrued expenses		23		27
Other non-current liabilities
Restructuring Reserve [Roll Forward]
Other noncurrent liabilities		22		18
Employee Severance
Restructuring Reserve [Roll Forward]
Beginning balance		45	[1]	41		90
Provision/(benefit)	[3],[4]	33		25		10
Utilization and other	[2]	(33)		(21)		(59)
Ending balance		45	[1]	45	[1]	41
Exit Costs
Restructuring Reserve [Roll Forward]
Beginning balance		0	[1]	0		0
Provision/(benefit)		0		1		3
Utilization and other	[2]	0		(1)		(3)
Ending balance		0	[1]	0	[1]	0
United States
Restructuring Reserve [Roll Forward]
Provision/(benefit)				7		2
International
Restructuring Reserve [Roll Forward]
Provision/(benefit)		$ 2		$ 19		$ 11

[1] At December 31, 2019 and 2018, included in Accrued Expenses ($23 million and $27 million, respectively) and Other noncurrent liabilities ($22 million and $18 million, respectively).

[2] Includes adjustments for foreign currency translation.

[3] The restructuring charges are associated with the following: • For the year ended December 31, 2019, International of $2 million and Manufacturing/research/corporate of $31 million. • For the year ended December 31, 2018, International of $7 million, and Manufacturing/research/corporate of a $19 million. • For the year ended December 31, 2017 International of $2 million, and Manufacturing/research/corporate of a $11 million.

[4] The restructuring charges for the year ended December 31, 2019, are primarily related to the acquisition of Abaxis and CEO transition-related costs. The restructuring charges for the year ended December 31, 2018, are primarily related to: • employee termination costs of $7 million in Europe as a result of initiatives to better align our organizational structure; • employee termination costs of $21 million related to the acquisition of Abaxis; and • a net reversal of employee termination costs of $3 million, and exit costs of $1 million as a result of our operational efficiency initiative and supply network strategy initiative launched in 2015. The restructuring charges for the year ended December 31, 2017, are primarily related to: • a net increase in employee termination costs of $2 million related to the operational efficiency initiative and supply network strategy initiative launched in 2015; • employee termination costs of $4 million related to the acquisition of an Irish biologic therapeutics company in the third quarter of 2017, and • employee termination costs of $4 million in Europe, as a result of initiatives to better align our organizational structure.